This report analyzes the disruptive themes that have driven M&A activity in Q3 2025 in the pharma Sector.
The global pharma sector in Q3 2025 witnessed deals worth $43 billion, a growth of 30% compared to Q3 2024. The Pharma sector recorded deal value worth $34 billion mega deals (defined as any deal valued at more than $1 billion) in Q3 2025, an increase of 67% compared to Q3 2024.
The global pharma sector in Q3 2025 witnessed deals worth $43 billion, a growth of 30% compared to Q3 2024. The Pharma sector recorded deal value worth $34 billion mega deals (defined as any deal valued at more than $1 billion) in Q3 2025, an increase of 67% compared to Q3 2024.
Report Scope
- This report provides an overview of merger and acquisition activity globally in Q3 2025 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q3 2025 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of the Pharma M&A Market - Q3 2025
- Pharma M&A Deals Analysis by Geography - Q3 2025
- Further Reading
- Report Authors
- Appendix 1: Deal Selection Criteria
- Appendix 2: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co Inc
- Genmab AS
- Pfizer Inc
- F. Hoffmann-La Roche Ltd
- Innosera ApS
- Sanofi
- Novartis AG
- AbbVie Inc
- Sino Biopharmaceutical Ltd
- Royalty Pharma Plc
- Lotus US Financing S.a r.l
- Otsuka Pharmaceutical Co Ltd
- Les Laboratoires Servier SAS
- Bausch Health Companies Inc
- Serb SAS
- Sanofi
- Concentra Biosciences LLC
- MannKind Corp
- Kite Pharma Inc
- Celltrion Inc
- Verona Pharma Plc
- Merus NV
- Metsera Inc
- 89bio Inc
- Bavarian Nordic AS
- Vicebio Ltd
- Tourmaline Bio Inc
- Gilgamesh Pharmaceuticals Inc
- LaNova Medicines Ltd
- BeOne Medicines
- Alvogen Inc
- Cantargia
- Kaerus Bioscience
- DURECT Corp
- Y-mAbs Therapeutics Inc
- Visirna Therapeutics
- iTeos Therapeutics Inc
- scPharmaceuticals Inc
- Interius BioTherapeutics Inc
- Eli Lilly
